Navigation Links
The Quigley Corporation Reports Fourth Quarter & 2007 Annual Results; Increases Investment to $6.5 million in Pharmaceutical R&D in 2007
Date:3/3/2008

on February 29, 2008 of its wholly owned subsidiary, Darius International Inc. ("Darius"), which constitutes the Health and Wellness segment, to InnerLight Holdings, Inc. The terms of the agreement include a purchase price of $1 million in cash without guarantees, warranties or indemnifications for the stock of Darius and its subsidiaries. The unaudited net book value of Darius at December 31, 2007 and 2006 approximate $124,000 and $2.4 million, respectively. Darius' net sales for 2007 and 2006 approximate $11.2 million and $15.3 million, respectively with a net loss for 2007 and 2006 approximating $600,000 and $1.2 million, respectively.

Over the last few years, net sales of the Health and Wellness segment have declined significantly resulting in continued losses, which is due to the continued reduction in the number of active independent distributor representatives, and the effects of ongoing litigation with the sponsor of its product line.

As the Company continues to review its current structure, ownership of Darius is no longer a benefit since losses by this segment have been a drain for the ongoing research and development costs associated with the ethical pharmaceutical segment. Also, separating this segment will help streamline the structure of the Company, which will focus on continuing operations in OTC product marketing and pharmaceutical research.

Pharmaceutical research and development costs associated with clinical studies for QR-333, including the Phase II(b), an investigational new drug for treating conditions associated with diabetic peripheral neuropathy, increased significantly during 2007 to $4.7 million from $1.9 million invested in 2006.

According to The World Health Organization estimates, more than 171 million people have diabetes worldwide. It is also estimated that 20 million people, representing approximately 7% of the United States population have diabetes of which some 60% will suffer from mild to severe nerve
'/>"/>

SOURCE The Quigley Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. The Quigley Corporation Announces Sale of Its Health and Wellness Segment
2. Cardiogenesis Corporation Reports Delay in Earnings Release and Conference Call
3. Dialysis Corporation of America Announces Fiscal Year 2007 Earnings Release Date
4. Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results
5. National Atlantic Holdings Corporation to Report Fourth Quarter and Year-End 2007 Earnings on March 17, 2008
6. Linkwell Corporations Skin Disinfectant Product Chosen for 2008 Beijing Olympic Games
7. Partners Center for Connected Health and EMC Corporation Launch New Web-Based Remote Monitoring Program to Help Employees Fight Hypertension
8. China Bionanometer Industries Corporation Announces New Products for China
9. Centene Corporation Unveils Winners of the 2008 Physician Summit Award
10. Dialysis Corporation of America Announces its Newest Center Opening in South Carolina
11. Harris Corporation Demonstrates Digital Signage(TM) Solutions for Dynamic, Rapid Communications within Healthcare Enterprises
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014 According to the Drama Method ... relationship guide that helps women easily get the attention of ... Vkool reveals in its review that this book can teach ... their man. The book also instructs them how to conquer ... in its Drama Method review that this book is divided ...
(Date:7/28/2014)... Dr. Alan Xenakis, MD announced today the release of ... new book, DOC X MD Funny Feelings translates ... style with humor and medical accuracy. The book is creatively ... answers to those age-old questions that most folks are embarrassed ... do mosquitoes bite some and not others? Why do folks ...
(Date:7/27/2014)... Recently, Wdsshop.de, a reliable online supplier of women’s ... prom dresses on its website. Now, all these ... 58% off. , “We are pleased to add the new ... specially created for those who are in need of fashionable ... in style. I think our clients will love them. Ladies, ...
(Date:7/27/2014)... shown that a powerful drug given at the time ... early risk of rejection, but that it also allows ... used after the operation. , The key results are ... the World Transplant Congress in San Francisco today. They ... the powerful combinations of treatments used to prevent early ...
(Date:7/27/2014)... why medication to treat asthma and pneumonia can become ineffective. ... that drugs widely used to treat lung diseases work with ... which is caused by an infection, affects around 1 in ... young children, the elderly, smokers and those with an underlying ... the UK are affected by asthma and the NHS spends ...
Breaking Medicine News(10 mins):Health News:The Drama Method Pdf Review Exposes Aaron Fox's Relationship Guide – Vkool.com 2Health News:The Drama Method Pdf Review Exposes Aaron Fox's Relationship Guide – Vkool.com 3Health News:New Book by Alan P. Xenakis, MD Reveals Mind and Body Mysteries 2Health News:Wdsshop.de Unveils New Prom Dresses To Expand The Online Market 2Health News:Kidney transplant drug halves the early risk of rejection and allows less toxic treatment 2Health News:Kidney transplant drug halves the early risk of rejection and allows less toxic treatment 3Health News:Drugs used to treat lung disease work with the body clock 2
... this Valentine,s Day and give the friends and family ... gift that will satisfy,their sweet tooth, warm their heart ... new Organic Chocolate Single Serve is a deep chocolate,nectar ... all of the,fat, cholesterol and calories," said Pam Dietz, ...
... A new company has joined the fight against MRSA ... have launched a new company, Inspiralis Ltd, based around ... enzymes that help DNA molecules to unravel and wind ... , DNA becomes tangled as a result of ...
... Nearly 90,000 Annual ... ... provider of,point-of-care charge capture technologies, today announced that its,customer, the ... Infusion Services Module., The Module, an extension of MedAptus, ...
... of Men With Erectile Dysfunction Are Smokers, NEW ... image and attractiveness, it does the exact opposite when ... According to recent studies, 60-percent of all men who ... partners burning,for more passion. In an effort to dramatically ...
... of the Cancion(R) System in Patients ... Hospitalized with Heart Failure, ... products company developing and marketing devices to,treat heart failure, announced ... Breaking Clinical Trial presentation at the,upcoming annual American College of ...
... Noyes announced today that,the firm represented The Riverside Company ... to Halyard Capital. The management team will,continue to have ... transaction,were not disclosed., "This is an excellent match ... winning healthcare and information franchise," said,Tom O,Connor, the Berkery ...
Cached Medicine News:Health News:Give Vitasoy's 'Liquid Love' for Heart Month! 2Health News:DNA with a twist: New company to search for cancer drugs and antibiotics 2Health News:Dana-Farber Cancer Institute Completes Deployment of MedAptus' Infusion Services Module 2Health News:Dana-Farber Cancer Institute Completes Deployment of MedAptus' Infusion Services Module 3Health News:The Best Way to Stoke Your Valentine's Fire: Don't Light Up 2Health News:Orqis(R) Medical's MOMENTUM Trial Abstract Accepted for Late Breaking Clinical Trial Presentation at the American College of Cardiology Annual Meeting 2Health News:Berkery Noyes Represented The Riverside Company on the Sale of HCPro Holdings, Inc. to Halyard Capital, LLC 2Health News:Berkery Noyes Represented The Riverside Company on the Sale of HCPro Holdings, Inc. to Halyard Capital, LLC 3
(Date:7/25/2014)... and Tobago , July 25, 2014 /PRNewswire/ ... Trinidad & Tobago Ministry of Health approved the ... that significantly increases the cure rate from Hepatitis ... with the genotype 1 virus. Telaprevir is available ... trade brand INCIVO®. Photo - ...
(Date:7/25/2014)... July 25, 2014  Acsis Inc., the market ... serialization solutions, has recently posted an article, ... current and future needs for companies, extended supply ... supply chain model no longer work today.  The ... the growth of mobile technology, machine to machine ...
(Date:7/25/2014)... July 25, 2014 According to ... "Global and China Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, ... Share, Growth, Trends and Forecast (Value and Volume), 2013 ... USD 19.99 billion in 2012 and is expected to ... 2019 to reach USD 32.24 billion in 2019. ...
Breaking Medicine Technology:The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3Acsis Addresses Questions on the Modern Supply Chain 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4
... by March of Dimes Grantee Offers Hope for Treatment ... new gene-based,technique has successfully prevented a rare craniofacial birth ... the same disorder, according,to new research funded in part ... is being published in the journal Nature Medicine,demonstrates the ...
... /Xinhua-PRNewswire-FirstCall/ -- Lotus Pharmaceuticals,Inc. (OTC Bulletin Board: ... in the People,s Republic of China ("PRC"), ... in the development of,isosorbide mononitrate sustained release ... and treatment of angina., Based on ...
Cached Medicine Technology:Molecular Therapy Succeeds in Preventing Craniofacial Birth Defect in Mice 2Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets 2Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets 3
... Pupillometry in Critical Care & Emergency ... a hand-held, cordless, and simple to use ... the measurement of the pupillary light reflex ... pupillary function which are not discernable to ...
...
Inquire...
Using proven 1064 nm technology for the treatment of deeper lesions, the Lumenis One Multi-Spot Nd:YAG module provides versatility allowing targeted treatment of leg veins, vascular lesions, facial w...
Medicine Products: